Eur Respir J. 2012 Jan;39(1):3-4.
Pulmonary hypertension in patients with sickle cell disease: not so frequent but so different.
Simonneau G, Parent F.
Pulmonary hypertension in patients with sickle cell disease: not so frequent but so different.
Simonneau G, Parent F.
Eur Respir J. 2012 Jan 26. [Epub ahead of print]
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era.
Jaïs X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, Vizza CD, Macdonald P, Humbert M, Hoeper MM.
Eur Respir J. 2012 Feb;39(2):313-8. Epub 2011 Jul 7.
The association between resting and mild-to-moderate exercise pulmonary artery pressure.
Whyte K, Hoette S, Herve P, Montani D, Jaïs X, Parent F, Savale L, Natali D, O'Callaghan DS, Garcia G, Sitbon O, Simonneau G, Humbert M, Chemla D.
J Heart Lung Transplant. 2012 Feb;31(2):150-8. Epub 2011 Dec 3.
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study.
Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.
Blood. 2012 Feb 16;119(7):1772-80. Epub 2011 Dec 20.
Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension.
Launay JM, Hervé P, Callebert J, Mallat Z, Collet C, Doly S, Belmer A, Diaz SL, Hatia S, Côté F, Humbert M, Maroteaux L.
Eur Respir J. 2012 Feb 23. [Epub ahead of print]
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.
Cottin V, Harari S, Humbert M, Mal H, Dorfmüller P, Jais X, Reynaud-Gaubert M, Prevot G, Lazor R, Taillé C, Lacronique J, Zeghmar S, Simonneau G, Cordier JF; the Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
Eur Respir J. 2012 Feb 23. [Epub ahead of print]
Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension.
Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM.
Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension.
Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM.
Eur Respir Rev. 2012 Mar 1;21(123):4-5. doi: 10.1183/09059180.00000512.
The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries.
Humbert M.
The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries.
Humbert M.
Chest. 2012 Mar 8. [Epub ahead of print]
Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension.
Cracowski JL, Degano B, Chabot F, Labarère J, Schwedhelm E, Monneret D, Iuliano L, Schwebel C, Chaouat A, Reynaud-Gaubert M, Faure P, Maas R, Renversez JC, Cracowski C, Sitbon O, Yaici A, Simonneau G, Humbert M.
Chest. 2012 Mar 29. [Epub ahead of print]
Pulmonary Langerhans Cell Histiocytosis associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.
Le Pavec J, Lorillon G, Jaïs X, Tcherakian C, Feuillet S, Dorfmüller P, Simonneau G, Humbert M, Tazi A.